Tyme Technologies’ Chief Medical Officer, Dr. Giuseppe Del Priore, Presents at 2016 ACOG Annual Clinical and Scientific Meeting

NEW YORK, June 06, 2016 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that its Chief Medical Officer (CMO), Dr. Giuseppe Del Priore joined an elite group of national and international experts to discuss cancer-related topics at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington, DC. As part of the “Lunch with the Experts” program, Dr. Del Priore led two dynamic small group discussions: Medical Treatment of HPV-Related Diseases and Medical Management of Dysplasia.

“We are extremely proud that Dr. Del Priore was chosen to share his expertise at this prestigious event,” said Michael Demurjian, Chief Operating Officer. “These critical knowledge-sharing conferences ultimately serve to deepen our understanding of cancer as a disease and are an invaluable aid in finding treatments.”

Dr. Del Priore, who joined Tyme as CMO and a member of the Medical Advisory Board in November 2015, previously served as founding National Director of Gynecologic Oncology of Cancer Treatment Centers of America (CTCA), where he was also its Southeastern Regional Director. Prior to that, Dr. Del Priore was an endowed Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine, Director of Gynecologic Oncology at New York Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, and Assistant Director of Gynecologic Oncology at New York University School of Medicine. He has authored and published more than 170 papers, book chapters and abstracts, and has written three books.

For more information, visit: www.tymetechnologiesinc.com.

About Tyme Technologies
Our research and development efforts are based on a proprietary platform technology, for which we retain global IP and commercial rights. Our lead program is SM-88, a proprietary combination drug product. We believe SM-88 is a first-in-class oncology therapy that increases the power of the body’s innate defenses to utilize oxidative stress to kill cancer cells. SM-88 is designed to penetrate only living cancer cells without toxic effects and without involving healthy body tissue. We believe that SM-88’s therapeutic potential is based on its ability to increase the availability of free radicals and promote their entry into cancer cells by stripping the cancer cells of their normal barriers to these toxic electrons. SM-88 is a combination of a proprietary novel molecule with three currently-marketed drugs that are generally considered safe for their already approved indications, which are in areas other than cancer treatment.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding Tyme’s future performance, and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. Forward-looking statements within this press release include, without limitation, statements regarding our drug development strategies, the therapeutic mechanisms of our drug candidates and our completed and planned clinical trials. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).

CONTACT: Contact:

Lisa M. Wilson,
In-Site Communications, Inc.